(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) on its New Drug Application (NDA) for tafamidis meglumine. The Agency is requesting the completion of a second efficacy study to establish substantial evidence of effectiveness prior to an approval. The Agency has also asked for additional information on the data within the current tafamidis NDA. Pfizer willmore...
Press Release Archive
June 17, 2012 - Have Americans Reached a New Era of Optimism about Aging?
(BUSINESS WIRE)--With 10,000 Americans turning 65 every day – and according to new research released today, a majority of them expect to live to nearly 90 – the celebration of older Americans is a developing trend, and more people are aspiring to live longer and better than ever before. As part of Pfizer’s mission to improve the health and well-being of people at every stage of life, the company is launching Get Old, a multi-year initiative supportedmore...
"The name best captures the company’s focus on partnership with veterinarians, livestock producers and companion animal owners by providing innovative products and solutions that advance animal health and human well-being,"
(BUSINESS WIRE)--Pfizer announced today that the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion regarding the marketing authorization of axitinib in the European Union (EU), for the treatment of adult patients with advanced renal cell carcinoma (RCC), a type of advanced kidney cancer, after failure of prior treatment with sunitinib or a cytokine. Axitinib, a kinase inhibitor, is an...
(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the United States Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Drugs Advisory Committee voted on Pfizer’s clinical data package for tafamidis meglumine. Tafamidis is a novel, investigational, oral therapy for the treatment of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) in adult patients with symptomatic polyneuropathy to delay neurologic impairment. Themore...
"He has more than 20 years of global experience in the pharmaceutical industry. Olivier is both a physician and proven business leader who understands the many challenges of today’s changing industry and healthcare landscape."
(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Pfizer’s oncology leadership team at an analyst and investor meeting on Sunday, June 3, 2012 at 6:00 p.m. Central Daylight Saving Time, in connection with the annual meeting of the American Society of Clinical Oncology (ASCO). To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “Pfizer Analystmore...
"This is the first exploratory fMRI study to investigate the mechanism of action of Lyrica in humans with fibromyalgia,"
(BUSINESS WIRE)--Pfizer Inc announced today that the Phase 3 INTORSECT (B1771003) study, evaluating TORISEL® (temsirolimus) in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after SUTENT® (sunitinib malate) therapy, did not meet the primary endpoint of prolonging progression free survival (PFS) when compared to sorafenib. Although PFS was numerically higher in patients treated with temsirolimus, the difference was not.
(BUSINESS WIRE)--New data will be presented on targeted cancer treatments from the Pfizer Oncology portfolio across three key therapeutic categories, including tumors of the kidney, lung and hematologic malignancies, at the Annual Meeting of the American Society of Clinical Oncology in Chicago, IL, from June 1-5. Approximately 100 abstracts featuring Pfizer’s cancer treatments and investigational compounds across 20 cancer types will be presented during themore...
(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with David Simmons, President and General Manager, Emerging Markets and Established Products, at the Bank of America Merrill Lynch 2012 Healthcare Conference on Thursday, May 17, 2012 at 8:00 a.m. Pacific Daylight Time. To listen to the webcast, visit our web site at www.pfizer.com and click on the “Bank of America Merrill Lynch 2012 Healthcaremore...
(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the Arthritis Advisory Committee to the U.S. Food and Drug Administration (FDA) voted 8-2 to recommend approval of the investigational agent tofacitinib for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). The Committee’s recommendation will be considered by the FDA in its review of the New Drug Application (NDA) for tofacitinib. The FDA has provided an
(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced new data presented at the 165th Annual Meeting of the American Psychiatric Association (APA) in Philadelphia on PRISTIQ® (desvenlafaxine) Extended Release Tablets 50 mg/day for the treatment of major depressive disorder (MDD) in adults,1 including a long-term relapse prevention study. These new data, and data from a study in peri- and post-menopausal women with MDD, add to the existing efficacy and safety
"The results of this study show the complexities of studying pain, particularly in a difficult-to-treat condition such as neuropathic pain associated with HIV neuropathy for which there are no approved medications in the United States,"
(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 randomized withdrawal design study for Lyrica (pregabalin) in patients with inadequately treated painful diabetic peripheral neuropathy (pDPN) did not meet its primary efficacy endpoint, change in endpoint mean pain score relative to baseline.
(BUSINESS WIRE)--Pfizer Inc.(NYSE:PFE) and Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX, TASE:PLX) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved ELELYSO™ (taliglucerase alfa) for injection, an enzyme replacement therapy (ERT) for the long-term treatment of adults with a confirmed diagnosis of type 1 Gaucher disease. ELELYSO is the first FDA-approved plant cell-based ERT for Gaucher disease. It is also themore...
April 30, 2012 - Pfizer Reports First-Quarter 2012 Results
(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE): ($ in millions, except per share amounts) First-Quarter 2012 2011(4
April 30, 2012 - Pfizer Inc. Issues Statement Regarding Pending Court Case
(BUSINESS WIRE)--Pfizer Inc. today issued the following statement regarding a pending court case in Utah: "The parties to Brigham Young University and Dr. Daniel Simmons v. Pfizer Inc. et al., a matter in the United States Court for the District of Utah, Central Division, announce that they have reached an amicable settlement on confidential terms. As part of the resolution, BYU will establish the Dan Simmons Chair in recognition of Dr. Simmons'more...
April 26, 2012 - Pfizer Hosts Annual Meeting Of Shareholders
(BUSINESS WIRE)--The board of directors of Pfizer Inc. today declared a 22-cent second-quarter 2012 dividend on the company’s common stock, payable June 5, 2012, to shareholders of record at the close of business on May 11, 2012. The second-quarter 2012 cash dividend will be the 294th consecutive quarterly dividend paid by Pfizer. “Through dividends and share repurchases, we returned approximately $15.2 billion to our shareholders in 2011,” said Ianmore...
(BUSINESS WIRE)--As part of a nationwide effort to help communities fight congestion, Pfizer Consumer Healthcare, the makers of Advil® Congestion Relief, stopped in St. Louis to help Kingdom House, a local social service provider, create space to help community needs. Currently, Kingdom House faces literal congestion; those in need are forced to discuss their challenges in a crowded area with others nearby. Not having a private area to discuss personal
Pages
Press release archive foot note
Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.
Stay on top of Pfizer breaking news: Get News Alerts by RSS. 
Stock Quote Disclaimer
20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.
 |
If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page. |
Current Stock Price
| . |
. . |
| %Change | . | 52 Wk. High | . |
| Day High | . | 52 Wk. Low | . |
| Day Low | . | Mkt. Cap(Bil) | . |
| Open | . | ||
| Prev Close | . | Symbol | . |
| Vol. | . | Exchange | . |
Online Pfizer Press Kit
Our press kit provides information that might help you write stories or simply find out more about Pfizer.